Before starting a trial, which element is most appropriate to be clearly specified in the protocol?

• A. Proposed statistical analysis features.
• B. Randomization plan.
• C. Marketing plan.
• D. Study title.

Answer: (A)

Defining the statistical analysis plan before the trial starts is essential. The protocol should clearly spell out how data will be analyzed, including the primary and secondary endpoints, the populations to be analyzed (for example, intention-to-treat vs. per-protocol), the statistical methods to be used, how missing data will be handled, and any plans for interim analyses or stopping rules. Pre-specifying these analyses prevents data-driven choices and protects the integrity and objectivity of study conclusions, which is a fundamental aspect of GCP and good clinical research practice.

A randomization plan is also documented in the protocol, but the emphasis here is on how the data will be analyzed rather than how participants are allocated. Marketing plans and the study title do not govern trial analysis or conduct in the same way, so they are not the element that needs to be clearly specified to safeguard the trial’s validity.